<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05103995</url>
  </required_header>
  <id_info>
    <org_study_id>ZJU-haplo-abo</org_study_id>
    <nct_id>NCT05103995</nct_id>
  </id_info>
  <brief_title>Impact of Donor-recipient ABO Matching on Haploidentical Stem Cell Transplantation</brief_title>
  <official_title>Impact of Donor-recipient ABO Matching on Patients' Outcome After Peripheral Blood Stem Cell Haploidentical Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Affiliated Jinhua Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>First Affiliated Hospital of Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the impact of donor-recipient ABO matching on outcome of peripheral blood stem cell&#xD;
      haploidentical hematopoietic stem cell transplantation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The impact of donor-recipient ABO compatibility on transplant outcomes had been evaluated in&#xD;
      different transplant settings, but had shown different results. The investigators set out to&#xD;
      investigate the impact of ABO incompatibility on post-transplant outcomes, engraftment&#xD;
      kinetics and blood product requirements, transfusion independence, the incidence of poor&#xD;
      graft function (PGF) in anti-T-lymphocyte globulin (ATG) based haplo-SCT with PBSC grafts.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2013</start_date>
  <completion_date type="Actual">October 1, 2021</completion_date>
  <primary_completion_date type="Actual">March 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>5-year Overall Survival</measure>
    <time_frame>5 year</time_frame>
    <description>5-year Overall Survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>5-year Non-relapse mortality</measure>
    <time_frame>5 year</time_frame>
    <description>5-year non-relapse mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-year cumulative incidence of chronic graft versus host disease</measure>
    <time_frame>5 year</time_frame>
    <description>5-year cumulative incidence of chronic graft versus host disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day cumulative incidence of neutrophils engraftment</measure>
    <time_frame>28 day</time_frame>
    <description>numbers of participants achieved neutrophils engraftment at 28 days post transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day cumulative incidence of platelets engraftment</measure>
    <time_frame>28 day</time_frame>
    <description>numbers of participants achieved platelets engraftment at 28 days post transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>365-day blood transfusion requirements</measure>
    <time_frame>365 day</time_frame>
    <description>numbers of blood products transfusion within 365-day after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative incidence of blood transfusion independence within 60 days after transplantation</measure>
    <time_frame>60 day</time_frame>
    <description>numbers of participants achieved blood transfusion independence within 60 days after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the 5-year cumulative incidence of poor graft function the incidence of poor graft function</measure>
    <time_frame>5 year</time_frame>
    <description>numbers of participants occurred poor graft function 5 years post transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the 5-year cumulative incidence of graft failure</measure>
    <time_frame>5-year</time_frame>
    <description>numbers of participants occurred graft failure 5 years post transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>100-day cumulative incidence of acute graft versus host disease</measure>
    <time_frame>100-day</time_frame>
    <description>100-day cumulative incidence of acute graft versus host disease</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">510</enrollment>
  <condition>Hematological Malignancies</condition>
  <condition>Haploidentical Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>ABO matched</arm_group_label>
    <description>Donor-recipient ABO matched</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Minor incompatibility</arm_group_label>
    <description>Donor-recipient minor incompatibility</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Major incompatibility</arm_group_label>
    <description>Donor-recipient major incompatibility</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bidirectional incompatibility</arm_group_label>
    <description>Donor-recipient bidirectional incompatibility</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>no intervention, just observation</description>
    <arm_group_label>ABO matched</arm_group_label>
    <arm_group_label>Bidirectional incompatibility</arm_group_label>
    <arm_group_label>Major incompatibility</arm_group_label>
    <arm_group_label>Minor incompatibility</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with malignant hematological diseases plan to receive allogeneic peripheral blood&#xD;
        stem cell transplantation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. The subjects or their legal representatives signed the informed consent before the&#xD;
        clinical study. 2. Subjects aged 15-70 years. 3. Patients with malignant hematological&#xD;
        diseases plan to receive allogeneic peripheral blood stem cell transplantation 4. Patients&#xD;
        have no suitable HLA identical sibling donor 5.Patients with malignant hematological&#xD;
        diseases plan to receive HLA haploidentical stem cell transplantation 6. Subjects with ECoG&#xD;
        score of 0-2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1.Patients have suitable HLA identical sibling donor 2. Patients with severe liver and&#xD;
        kidney function (alanine aminotransferase &gt; 2.5 times of the upper normal limit, serum&#xD;
        creatinine &gt; 1.5 times of the upper normal limit), cardiopulmonary dysfunction (cardiac&#xD;
        function NYHA III / IV, cardiac ejection fraction &lt; 50%, severe obstructive or restrictive&#xD;
        ventilation dysfunction); 3. Patients with active infection; 4. patients diagnosed with&#xD;
        aplastic anemia before transplantation or died within 2 months after transplantation; 5.&#xD;
        Subjects with ECoG score &gt; 2; 6. Patients with secondary tumor; 7. Patients who cannot&#xD;
        independently choose to enter or exit clinical trials due to serious central nervous system&#xD;
        disease or mental disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The first Affiliated Hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated Jinhua hospital of Zhejiang University</name>
      <address>
        <city>Jinhua</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 10, 2021</study_first_submitted>
  <study_first_submitted_qc>October 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2021</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital of Zhejiang University</investigator_affiliation>
    <investigator_full_name>Yi Luo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>haploidentical stem cell transplantation</keyword>
  <keyword>hematological malignancies</keyword>
  <keyword>ABO incompatibility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

